Endologix, Inc. (NASDAQ:ELGX)

CAPS Rating: 3 out of 5

The Company develops, manufactures, sells and markets minimally invasive therapies for the treatment of cardiovascular disease.

Results 1 - 9 of 9

Recs

0
Member Avatar TSIF (99.96) Submitted: 3/11/2014 9:37:30 PM : Outperform Start Price: $13.76 ELGX Score: +0.48

Endologix, Inc was hit hard by earnings and forward guidance. Based on their forcast, they will lose money again in all of 2014, making them to some "dead money". In this case, the bottom may be lower, even after a 25% price "reset".

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of aortic disorders. This can be a risky market to enter with strict FDA oversite and medical preferences, payment schedules, etc.

Their P/B is a little high at 8 with negative cash flow,but with $126 Million in cash after a debt offering, they should be able to weather another year. Companies at this stage growing revenue also grow expenses as they build up sales and infrastructure. If they are NOT growing revenues, they should be avoided. With growing revenues and growing S&G, the question becomes how patient, how much cash, will they need to dilute, etc, until they become cash flow postive. A company on the cusp of profitability can either stagnate or EPS can soar when the magical day comes.

Fourth quarter revenue growth of 21%, gross margin of 75%, expanded sales in Europe, Doctor training progressing...only forcase 11-15% growth in 2014 which disappointed and sounds light.

VERY solid institutional holdings, something I like to see.

I think Endologix has potential and this sell off could make a good entry point for a patient investor, which I usually am not...but needs watched a few quarters.

Recs

0
Member Avatar loangolfer (< 20) Submitted: 12/17/2012 9:09:10 AM : Outperform Start Price: $13.32 ELGX Score: -29.43

Cabot says $45 in '13

Recs

0
Member Avatar whatevmatil (< 20) Submitted: 3/23/2012 12:24:02 PM : Outperform Start Price: $14.30 ELGX Score: -39.98

Once/if Nellix and Ventana get approved, this stock should fly.

I hesitate to rate this in caps due to volitility, but whatever, I think it will go up ultimately.

Recs

0
Member Avatar mgebremichael (< 20) Submitted: 3/7/2012 10:52:00 AM : Outperform Start Price: $12.48 ELGX Score: -29.56

Small company with strong growth potential. Company develops and sales devices to help with aortic disorders.

Recs

0
Member Avatar lola99999 (< 20) Submitted: 12/16/2009 9:55:51 PM : Outperform Start Price: $4.80 ELGX Score: +125.36

ELGX

Recs

2
Member Avatar smoothbore09 (< 20) Submitted: 9/6/2008 6:09:01 PM : Outperform Start Price: $2.70 ELGX Score: +381.39

Endologix is releasing two important new products in the late fall of 2008 and early 2009. Both are PMA supplements, so FDA approval is pretty much in the bag. The first is a new 34MM cuff size that comprises about 15-20% of the AAA market (which is growing extremely fast), which previously has not been available to them. This should impact revenues and EPS quite favorably in 2009. Another important product that will have a huge impact on sales in 2009 is the Visiflex IS delivery system for the Endologix Powerlink ELG device. Endologix already has the "Best in Class" safety data for AAA stents. Now with the Visiflex IS they will have the best, doc-friendly, delivery system for their device. This should have a profound impact by late 2009 and beyond. One could expect their current market share of 5% to be growing to 15% or so in a couple years with these important additions to their product line. The new CEO McDermott is smart and well liked by his people. He brings 25 years of cardiovascular experince to Endologix. As well, he lured another top exec from CR Bard over to Endologix recently to be the VP of sales. Between them they have nearly 50 years of medical sales experience. Great product + great management = SUCCESS.

Recs

2
Member Avatar samaha1 (< 20) Submitted: 1/27/2007 11:58:54 AM : Outperform Start Price: $4.50 ELGX Score: +176.71

Increasing sales quarter over quarter has boosted the price. Outlook is strong wth a good product pipeline. I think a future buyout could be in the offing by any one of a number of larger competitors

Recs

0
Member Avatar ramkitty (< 20) Submitted: 12/4/2006 7:37:19 PM : Outperform Start Price: $3.67 ELGX Score: +248.16

virus terminator

Recs

0
Member Avatar mikehux (89.59) Submitted: 10/29/2006 9:04:21 PM : Outperform Start Price: $3.87 ELGX Score: +224.64

new product

Results 1 - 9 of 9

Featured Broker Partners


Advertisement